RIGAKU
9.5.2024 16:01:35 CEST | Business Wire | Press release
Rigaku Corporation, a Rigaku Holdings Group company and Rigaku global solution partner in X-ray analytical equipment (head office: Akishima, Tokyo; president and representative director: Jun Kawakami; hereinafter “Rigaku”), has completed analysis of particles from 101955 Bennu, a near-Earth carbonaceous asteroid classified as a type B. The analysis was performed using ZSX Primus IV, a wavelength dispersive X-ray fluorescence spectrometer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508939191/en/
ZSX Primus IV (Photo: Business Wire)
The particles from Bennu are a sample obtained by OSIRIS-Rex, a spacecraft of the United States National Aeronautics and Space Administration (NASA). This analysis constitutes the second time Rigaku has been tasked with conducting analysis related to Bennu. On the first occasion, in December 2023, Rigaku measured water and carbon content in a sample from the carbonaceous asteroid using thermoanalysis.
The X-ray fluorescence spectrometry was conducted by the Rigaku Application Laboratory XRF Analytical Group in the presence of Professor Hisayoshi Yurimoto of the Faculty of Science, Hokkaido University, who directed the chemical analysis of samples brought back from the asteroid Ryugu by the Hayabusa 2 spacecraft.
The purpose of the analysis was to ascertain the content of major and trace elements including carbon and oxygen in sample. In the current measurements, quantitative analysis was performed on 26 elements Results of thermoanalysis and X-ray spectrometry were combined to learn about the history of Bennu and its similarities and differences with Ryugu.
The analysis of Bennu is now proceeding by worldwide project teams. A unique feature of the work of the Japan team, under the direction of Professor Yurimoto, is the application of thermoanalysis using thermogravimetry along with mass spectrometry and X-ray spectrometry using a wavelength dispersive X-ray fluorescence spectrometer.
One advantage of the Rigaku approach to thermoanalysis is that quantitative-analytical equipment is used in tandem, enabling Rigaku to separate and measure each element and type of molecule, with the result that unprecedented data can be obtained. Moreover, X-ray fluorescence spectrometry plays an exceptionally vital role: As the research method shifts toward inductively coupled plasma mass spectrometry (ICP-MS), X-ray fluorescence spectrometry can analyze major components such as carbon, oxygen, silicon and sulfur that are difficult to analyze using ICP-MS.
Professor Yurimoto commented: “The performance of the equipment is obviously vital, but in the end, what makes the difference is people. When conducting analysis on the leading edge of the field, the question of who does the analysis is paramount. I asked Rigaku to perform the analysis because this company brings to the table not only outstanding equipment but also superb engineers.”
Rigaku will continue to pursue close partnership with academia, contributing to the development of society through the advance of science and technology.
Related information
-
Press release regarding thermoanalysis conducted in December 2023
URL: https://rigaku.com/about/news-and-press-releases/rigaku-analyzes-samples-from-nasa?hsLang=en
Results of Rigaku’s Participation in the Initial Analysis Project of Ryugu Sample
In June 2019, Rigaku took part in the Ryugu project as a joint research partner. In 2021, the content percentages of elements in the sample from Ryugu were determined using ZSX Primus IV, a wavelength dispersive X-ray fluorescence (WDXRF) spectrometer. Measurements using TG-DTA/GC‐MS determined that the moisture content of the sample from Ryugu differed from that found in meteorites of carbonaceous chondrite, which are thought to reflect the mix of elements in the primordial solar system. These data now serve as the basic data from the Ryugu sample that research groups around the world are using to conduct a wide range of analyses.
Rigaku’s analytical results are cited in a paper by the chemical analysis team (led by Prof. Yurimoto) of the initial analysis team of the Hayabusa 2 mission, and are published in Science, a US-based scientific journal.
About The Rigaku Group
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including in its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”
For details, please visit rigaku.com (As of November 30, 2023)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508939191/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
